Cryz S J, Kaper J, Tacket C, Nataro J, Levine M M
Swiss Serum and Vaccine Institute, Berne.
Dev Biol Stand. 1995;84:237-44.
In many controlled studies, CVD103-HgR has been shown to be safe and immunogenic and to offer a significant degree of protection against experimental cholera after a single dose. Its minimal excretion and limited ability to compete and survive in various ecosystems indicate that this strain presents little risk to the environment. Furthermore, the potential of CVD103-HgR to regain virulence by acquisition of the CT A or LT A gene is extremely remote even under optimal conditions. Therefore, CVD103-HgR possesses those traits desired in a live oral attenuated vaccine produced by recombinant DNA technology.
